Dr. Abhishek Kanugo

Scopus Publications

Formulation Development and Evaluation of Fast Dissolving Sublingual Film of Apixaban: Design of Experiment-Based Approach
Abhishek Kanugo, Mohammad Adnan
Indian Journal of Pharmaceutical Education and Research, 2026
Development Optimization, and Characterization of Solid Lipid Nanoparticles of Entacapone for Treatment of Parkinson Disease
Kunal Mundada, Kanchan Chaudhari, Milind Wagh, Abhishek Kanugo
Indian Journal of Pharmaceutical Education and Research, 2026
Application of sustainable QbD based HPLC method for quantification of carboxylic-diphenyl methane drug ambrisentan loaded in solid lipid nanoparticles
Mohit Singh, Hemant Kumar Tatapudi, Abhishek Kanugo, Pavan Kumar Jaini, Mohana Vamsi Nuli
Sustainable Chemistry One World, 2026
Neusilin US2 based Liquisolid Blends of Azelnidipine: A QbD Approach for Improvement of Solubility and Bioavailability
Rutik Jukti, Abhishek Kanugo
International Journal of Pharmaceutical Sciences and Nanotechnology, 2026
Background: The Liquisolid compact technique encompasses the incorporation of a non-volatile solvent for the enrichment of solubility and dissolution percentage of hydrophobic drugs which generates liquid medicament. The carrier and coating agent adsorb the liquid load and thereby reconvert them into the freely flowing and compressible powder for solid orals. Rationale: The existing work is primarily dedicated to the estimation of the flowing potential of Neusilin US2 on the Liquisolid blends of Azelnidipine. The mark improvement in solubility and dissolution rate was achieved through the Liquisolid compact technique. Methods: The various non-volatile oil was utilized for the improvement of solubility of AZN and PEG 400 was best out of them. The drug-excipient interactions were confirmed with FTIR and DSC. The optimization software Design of Expert (Stat Ease Version 13) was incorporated which showed 12 trial runs for Box-Behnken design. The quantity of DCP (X1), Neusilin US2 (X2), and cross carmellose sodium (X3) were independent variables, and disintegration (Y1), and dissolution (Y2) were considered dependable parameters Results: The ANOVA models for both these dependable variables were significant with p-values of 0.0311 and 0.0097 correspondingly. The results of independent parameters were showed with Contour and surface response plots. The optimized formulation F1 showed a good flowability index, the least disintegration time (4.07 min), and the highest dissolution rate (99.40 %). Conclusion: The significant therapeutic efficacy of Azelnidipine was attained by enhancing the solubility and dissolution rate. Neusilin US2 showed great adsorption potential which minimizes the quantity of carrier and coating agent.
Harnessing the Potential of Natural Nutraceuticals Against Huntington’s Disease
Abhishek Kanugo, Yogeeta Agrawal
Current Topics in Medicinal Chemistry, 2026
Neurodegenerative disorders (NDDs) are a major global health concern and the fifth leading cause of death worldwide. Huntington's disease (HD) is an NDD regarded as a rare, genetic, and advanced disease that occurs due to the duplication of cytosine, adenine, and guanine (CAG) trinucleotide repeats on chromosome 4p, located in the Huntingtin gene (HTT). There is no specific therapy available for HD. This review examines current evidence on various nutraceuticals as therapeutic or preventive agents in HD and their benefits in protecting against neuronal damage, oxidative stress, mitochondrial dysfunction, and combating excitotoxicity and neuroinflammation. Moreover, the beneficial role of nutraceuticals in HD involves averting defective energy metabolism, protein misfolding and aggregation, and epigenetic modulation, as well as strengthening cognitive and behavioral health. Nutraceuticals are naturally derived, bioactive components generally available in foods, dietary supplements, and herbal products, and they contribute to health promotion and disease prevention. These nutraceuticals possess potent antioxidant, anti-inflammatory, and neuroprotective properties, which help minimize the risk of HD. Moreover, antibacterial, antiviral, antimicrobial, anticancer, antiaging, antidiabetic, antihyperlipidemic, and immunobooster characteristics attract a large population worldwide. The wide availability of nutraceuticals in fruits, vegetables, and several naturally occurring foodstuffs supports their accessibility. These nutraceuticals function by stabilizing mitochondrial function, counteracting calcium overload, minimizing oxidative stress, and preventing inflammatory responses, among other mechanisms. The wide acceptance and demand for these nutraceuticals are due to their multifunctional role, economic benefits, and safety profile. The most promising nutraceuticals in the prevention and therapy of HD discussed are Curcumin, Resveratrol, Quercetin, Epigallocatechin Gallate, Hesperidin, Coenzyme Q10, Kaempferol, Silymarin, Astaxanthin, Lycopene, and Rosmarinic acid.
Formulation Development and Evaluation of Self-Microemulsifying Drug Delivery System (SMEDDS) of Azelnidipine for Hypertension
Rutik Jukti, Abhishek Kanugo
Indian Journal of Pharmaceutical Education and Research, 2026
Recent Advancements in Diagnosis and Targeted Therapy of Pancreatic Cancer
Jayesh Patil, Abhishek Kanugo
Anti Cancer Agents in Medicinal Chemistry, 2026
Introduction:: Pancreatic Cancer (PC) is an exceptionally belligerent and lethal malignancy owing to failure in prognosis and limited existing therapies. Pancreatic Ductal Adenocarcinoma (PDAC) mostly originates from ductal cells, with a survival rate of less than 5 years. This cancer is predominantly caused by genetic abnormalities in the exocrine pancreas, such as KRAS and p53, which contribute to tumor growth and progression. Objective:: Our previously published article on PC taught us that there is an utmost need to identify novel biomarkers for diagnosis and targeted therapy approaches to improve survival rates in patients. Conventional radiotherapy and nanotechnology-based approaches show limited success compared to targeted therapy. Method:: A comprehensive literature search was conducted in PubMed, Science Direct, Scopus, Bentham Science, Google Scholar, ACS Journals, and Taylor and Francis journals and Web of Science databases using keywords related to Pancreatic Ductal Adenocarcinoma (PDAC), biomarkers, and targeted therapies. Articles published in English over the past two decades were screened, and studies focusing on novel biomarkers and therapeutic strategies were included for this review. Results:: Recent innovations in PDAC treatment include novel biomarkers (genetic markers, proteomic biomarkers, metabolism-related biomarkers, epigenetic markers, liquid biopsy, Pancreatic Cancer Stem Cell (PSCC) biomarkers, circulating biomarkers, and tissue biomarkers) that facilitate early diagnosis and thus minimize mortality rates. The current review highlighted the utmost need for novel targeted approaches (targeting DNA repairing and Microsatellite instability, targeting epigenetic alteration, targeting key Signaling pathways, targeting the stroma, Fibrosis, and extracellular matrix, and drug conjugate inhibitors) that enhance the specificity and efficacy against cancer cells, reduce the injury to healthy tissue, and improve survival rates. Discussion:: Targeted therapy also focuses on the specific molecular characteristics of cancer cells, providing a possible alternative to traditional therapies. Conclusion:: To summarize, the shifting landscape of cancer treatment, particularly for PC, requires further study of targeted innovative combination therapies to improve patient survival while addressing the major limitations of traditional treatments. Several such products are in clinical trials, which have benefited patients with new hope suffering from PDAC.
Recent Advances in Diagnosis, Artificial Intelligence, and Nanocarrier-based Therapy of Bladder Cancer: Current Status and Future Perspectives
Sufiya Qureshi, Abhishek Kanugo
Mini Reviews in Medicinal Chemistry, 2026
Bladder Cancer (BC) mostly originates in urothelial cells and remains one of the most aggressive and fatal forms of cancer. The rate of proliferation of malignant cells is extremely high, resulting in high mortality rates globally. The prognosis of BC is very poor and limited, which results in an advanced stage of cancer. Conventional therapy, chemotherapy, and radiotherapy show poor survival rates with high recurrence and mortality. Hence, there is an utmost need for novel biomarkers that indicate and warn of any abnormalities before cancer progresses to an advanced stage. The novel biomarkers comprised Bladder Tumor Antigen (BTA), BTA-TRAK, BTA Stat, NMP22 Bladder Chek, NMP22 enzyme-linked immunosorbent assay (ELISA), UC Antigen, Survivin, Epidermal Growth Factor Receptor (EGFR), Nuclear Matrix Protein 22 (NMP22), and various miRNAs (e.g., miR-21, miR-145), etc. The state-of-the-art review illustrates the symptoms and signs, causes, pathophysiology, and types of BC. The nanotechnology-based approaches implemented are lipidbased NPs (Liposomes, SLN, NLC, Nanoemulsion), polymer-based (Polymeric micelles, Dendrimers, hydrogels), inorganic NPs (QDs, mesoporous silica), Metal-based NPs (Gold, Silver, Copper, Platinum, core-shell, and magnetic NPs), carbon-based (CNTs, GO, carbon QDs, and nanodiamonds). Moreover, recent clinical trials related to BC were also listed. Liposomes, polymeric NPs, Gold NPs, QDs, mesoporous silica, CNTs, GO, etc. showed the most promising results. Various strategies to overcome resistance in BC were explored. Recent advances in AI and ML have enabled the prediction of treatment response, enhancing diagnosis, optimizing therapy selection, and the minimization of trial-and-error approaches. Moreover, nanotechnology has assisted precision medicine, further boosting patients' survival and hope.
Formulation Optimization and Evaluation of Patented Solid Lipid Nanoparticles of Ambrisentan for Pulmonary Arterial Hypertension
Harshada Shewale, Abhishek Kanugo
Recent Patents on Nanotechnology, 2026
Background: Ambrisentan is a new endothelin receptor antagonist extensively used to manage pulmonary or pulmonary arterial hypertension. Objective: The therapeutic efficacy of Ambrisentan is limited due to its reduced solubility, higher log P (3.4), and thus less bioavailability. The recent investigation was concentrated on the improvement of solubility, and bioavailability of Ambrisentan for the therapy of hypertension via solid lipid nanoparticles (SLN) administered orally. Methods: XRD evaluated the compatibility of Ambrisentan with lipids with FTIR, DSC, and crystalline nature. The SLN was developed by High-pressure homogenization method. The Glyceryl monostearate and Tween 80 indicated the highest solubility, hence selected. The optimization was performed with Box-Behnken Design considering the concentration of GMS (X1), Tween 80 (X2), stirring speed (X3) as independent factors and particle size (Y1), entrapment efficiency (Y2) as dependent factors. The Patents on the SLN are Indian 202321053691, U.S. Patent, 10,973,798B2, U.S. Patent 10,251,960B2, U.S. Patent 2021/0069121A1 and U.S. Patent 2022/0151945A1. Results: The optimized batch F1 showed particle size (130 nm), ZP (-18.9 mV), and entrapment efficiency (85.73 %). The dual release pattern (prompt and sustained) was achieved with the SLNloaded Ambrisentan for about 24 hours. The lyophilized sample was subjected to SEM, which also revealed a spherical shape of a colloidal dispersion with a particle size of 126 nm. Hence, the F1 batch is highly recommended for solid oral delivery and also for the pilot-plant scale-up. Conclusion: A marked improvement in the solubility and dissolution of Ambrisentan was attained with the SLN. Moreover, the sustained delivery via the oral route enabled the patient's comfort, compliance, and therapeutic efficacy.
Recent Advances in Antimicrobial Proteins and Peptides: A Promising Clinical Breakthrough and Patent Landscape
Sakshi Patel, Sanjay Sharma, Abhishek Kanugo
Current Protein and Peptide Science, 2026
Antimicrobial resistance (AMR, when microbes stop responding to medicines) is a growing worldwide concern calling for novel alternatives to conventional antibiotics. Because of their wide range of efficacy, ability to support the body’s natural defenses, and possible use in the treatment of cancer and inflammation-related illnesses, antimicrobial peptides (AMPs, short chains of amino acids that kill harmful microbes) and proteins stand out among these substitutes. In contrast to standard antibiotics, AMPs act against several cellular targets, making it harder for microbes to become drug-resistant. Despite challenges such as stability, scalability of production, and regulatory constraints, this review discusses recent progress in advancing the clinical utility of AMPs through synergistic approaches with approved drugs and sophisticated delivery systems. It highlights the strategic integration of biotechnological advancements with established AMP therapy, potentially providing efficient and cost-effective treatment options for infections that no longer respond to standard antibiotics. These trends position AMPs as next-generation therapeutics to address global health challenges.
Innovative Immunotherapy and Its Transformative Impact on Gastric Adenocarcinoma: A Comprehensive Review of the Disease’s Origins, Epidemiology, Classification, Diagnosis, and Treatment Options
Upasana, Abhishek Kanugo, Sankha Bhattacharya
ACS Pharmacology and Translational Science, 2025
Sustained release of Ambrisentan solid lipid nanoparticles for the treatment of hypertension: Melt emulsification method
Harshada Shewale, Abhishek Kanugo
Annales Pharmaceutiques Francaises, 2025
Design optimization and evaluatıon of polyvinyl alcohol based oral thin film of apixaban
Mohammad Adnan Raza, Dr. Abhishek Kanugo
Journal of Research in Pharmacy, 2025
Recent advances in nanotechnology for the diagnosis and therapy of melanoma skin cancer
Abhishek Kanugo
Advancements in Cancer Research Exploring Diagnostics and Therapeutic Breakthroughs, 2025
Applications of advanced nanocarriers in the theranostics of melanoma skin cancer
Abhishek Kanugo
Advancements in Cancer Research Exploring Diagnostics and Therapeutic Breakthroughs, 2025
Recent advances in immunotherapy-based approaches for the therapy of melanoma skin cancer
Abhishek Kanugo, Rutik Juktee
Advancements in Cancer Research Exploring Diagnostics and Therapeutic Breakthroughs, 2025
Advancements in cancer research: Exploring diagnostics and therapeutic breakthroughs
Advancements in Cancer Research Exploring Diagnostics and Therapeutic Breakthroughs, 2025
Preface
Sankha Bhattacharya, Mayank Sharma, Amit B. Page, Dhrubojyoti Mukherjee, Abhishek Kanugo
Advancements in Cancer Research Exploring Diagnostics and Therapeutic Breakthroughs, 2025
Design Optimization and Evaluation of Patented Fast-Dissolving Oral Thin Film of Ambrisentan for the Treatment of Hypertension
Abhishek Kanugo
Recent Patents on Nanotechnology, 2025
Recent Advances in Artificial Intelligence and Nanotechnology-Driven Strategies for Diagnosis and Therapy of Ocular Diseases
Abhishek Kanugo, Nikeeta Teli
Current Drug Delivery, 2025
Recent Developments in Nanotechnology and Immunotherapy for the Diagnosis and Treatment of Pancreatic Cancer
Komal Sindhi, Abhishek Kanugo
Current Pharmaceutical Biotechnology, 2025
Recent Advances in Immunotherapy and Targeted Therapy of Triple Negative Breast Cancer
Harshada Shewale, Abhishek Kanugo
Current Pharmaceutical Biotechnology, 2025
Development Optimization and Evaluation of Lipid-Based Nanoparticles of Apixaban by Melt Emulsification Method
Krishna Wagele, Abhishek Kanugo
Current Trends in Biotechnology and Pharmacy, 2025
Recent Advancements in Nanoparticles-based Approaches for the Theranostics of Glioblastoma Multiforme
Jugal Mandan, Dr. Abhishek Kanugo
Current Pharmaceutical Biotechnology, 2025
Integrated QbD Approach for the Development of Liquisolid Compact of Apixaban for Improvement of Solubility and Dissolution Rate
Sanjivani Rai, Abhishek Kanugo
Research Journal of Pharmacy and Technology, 2025
Importance of Synbiotic for the Management of Colorectal Cancers
Role of Probiotics in Cancer Management, 2025
Surgical Advancements, Immunotherapy, Targeted and Conventional Therapies, Biopsy, Colposcopy, and Pap Smear Integration in the Management of Cervical Cancer
Siddhi Wargantiwar, Sankha Bhattacharya, Abhishek Kanugo
Current Medicinal Chemistry, 2025
Formulation Optimization and Characterization of Solid Lipid Nanoparticles of Apixaban
Laukik Mulay, Namita Hegde, Abhishek Kanugo
Recent Patents on Nanotechnology, 2025
Sustained Delivery of Dolutegravir Sodium for Better Management of HIV/AIDS via Solid Lipid Nanoparticles
Mohit Singh, Pawan Kedar, Abhishek Kanugo, Amit Bukkawar
Current HIV Research, 2025
Novel Strategies for the Treatment of Lung Cancer: An In-depth Analysis of the Use of Immunotherapy, Precision Medicine, and Artificial Intelligence to Improve Prognoses
Pawan Kedar, Sankha Bhattacharya, Abhishek Kanugo, Bhupendra G. Prajapati
Current Medicinal Chemistry, 2025
Design and Development of Fast-dissolving Tablets of Apixaban using Single Coprocessed Excipient
Sourabh Jaiswal, Abhishek Kanugo
International Journal of Pharmaceutical Sciences and Nanotechnology, 2024
Design Optimization and Evaluation of Solid Lipid Nanoparticles of Azelnidipine for the Treatment of Hypertension
Tejas Dugad, Abhishek Kanugo
Recent Patents on Nanotechnology, 2024
BOX BEHNKEN MODEL-BASED LIQUISOLID COMPACT TECHNIQUE FOR THE IMPROVEMENT OF SOLUBILITY AND DISSOLUTION RATE OF AZELNIDIPINE
Dr. Abhishek Yogeshwar Kanugo, Rutik Jukti
Bulletin of Pharmaceutical Sciences Assiut, 2024
Biomedical Applications of Cellulose
Abhishek Kanugo, Pallavi Chaudhari, Rupesh K. Gautam
Biopolymers for Biomedical Applications, 2024
Formulation and Characterization of Self-Microemulsifying Drug Delivery System (SMEDDS) of Sertraline Hydrochloride
Sanjay Sharma, Abhishek Kanugo, Tejvir Kaur, Deepak Choudhary
Recent Patents on Nanotechnology, 2024
Recent Advancement of Microneedle Technique in Diagnosis and Therapy of Diseases
Abhishek Kanugo
International Journal of Pharmaceutical Sciences and Nanotechnology, 2023
Targeted delivery of panitumumab-scaffold bosutinib-encapsulated polycaprolactone nanoparticles for EGFR-overexpressed colorectal cancer
Sankha Bhattacharya, Vipan Kumar Parihar, Neeraj Singh, Ketan Hatware, Amit Page, Mayank Sharma, Mahendra Kumar Prajapati, Abhishek Kanugo, Datta Pawde, Saurabh Maru, Girdhari Lal Gupta, Sunil Kanvinde
Nanomedicine, 2023
Neusilin US2 based Liquisolid Compact technique for the enhancement of solubility and dissolution rate of Olmesartan: Box-Behnken design approach
Abhishek KANUGO, Anushka THANVI
Journal of Research in Pharmacy, 2023
pH-dependent pulsatile delivery of Ambrisentan for the treatment of hypertension
Abhishek KANUGO, Ronit DHAGE
Journal of Research in Pharmacy, 2023
Formulation Optimization and Evaluation of Nanocochleate Gel of Famciclovir for the Treatment of Herpes Zoster
Abhishek Kanugo, Ashwini Deshpande, Rahul Sharma
Recent Patents on Nanotechnology, 2023
Pharmacophore modeling
Maheshkumar Borkar, Arati Prabhu, Abhishek Kanugo, Rupesh Kumar Gautam
Computational Approaches in Drug Discovery Development and Systems Pharmacology, 2023
Determination of Olmesartan in Bulk and Pharmaceutical Dosage Forms through the Development and Validation of Stability-indicating RP-HPLC Method
Jagdish K. Sahu, Akshita A. Agrawal, Shilpa Dawre, Abhishek Kanugo
Drug Metabolism and Bioanalysis Letters, 2023
Recent Advances of Nanotechnology in the Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC)
Abhishek Kanugo, Rupesh K. Gautam, Mohammad Amjad Kamal
Current Pharmaceutical Biotechnology, 2022
Recent advancement of nanotechnology in functional foods: Applications perspectives
Abhishek Kanugo, Rajat Goyal, Sanjay Sharma, Rupesh Kumar Gautam
Nanotechnology in Functional Foods, 2022
Formulation optimization and evaluation of oral thin film of bilastine for the treatment of allergic conditions
Abhishek KANUGO, Yash GANDHI
Journal of Research in Pharmacy, 2022
Improvement of solubility and dissolution rate of Repaglinide by Liquisolid Compact technique: QbD approach
Mangesh GODBOLE, Amol THANGAN, Abhishek KANUGO
Journal of Research in Pharmacy, 2022
Design and development of solid lipid nanoparticles of tazarotene for the treatment of psoriasis and acne: a quality by design approach
Sanjay Sharma, Abhishek Kanugo, Juilee Gaikwad
Materials Technology, 2022
Liquisolid-pellets technique: A recent technique for enhancing solubility and bioavailability of drugs
ABHISHEK KANUGO
International Journal of Applied Pharmaceutics, 2020
New and novel approaches for enhancing the oral absorption and bioavailability of protein and peptides therapeutics
Abhishek Kanugo, Ambikanandan Misra
Therapeutic Delivery, 2020
Development of pulsatile drug delivery for chronotherapeutics of hypertension
A. Y. Kanugo, N. I. Kochar, A. V. Chandewar
International Journal of Drug Delivery Technology, 2017
Design and evaluation of enteric compression-coated tablet for chronotherapeutic drug delivery
Asian Journal of Pharmaceutics, 2017

Dr. Abhishek Kanugo

EDUCATION

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS